To summarize the available evidence, issues, and future trends in optimizing stem cell therapies for osteonecrosis, highlighting its clinical significance.
Key Findings:
Osteonecrosis leads to bone architecture weakness and joint dysfunction due to ischemia.
Key risk factors include traumatic injuries, corticosteroid use, systemic diseases such as lupus and sickle cell anemia.
Interpretation:
SCT may offer a biological repair option for osteonecrosis, potentially addressing underlying physiological deficiencies and improving patient outcomes.
Limitations:
Inconsistent quality of stem cells used in treatments.
Non-standardized protocols across clinical applications.
Optimizing SCT for osteonecrosis requires addressing current limitations and enhancing understanding of the osteonecrotic microenvironment to improve future research directions.
